Task Force on Climate-related Financial Disclosures (TCFD) Statement FY25

As one of the largest veterinary groups, we have a responsibility to use our scale and influence to reduce greenhouse gas emissions and improve standards of sustainability, both within our own operations, and then more widely in the veterinary profession. As well as reducing the impacts of our direct and indirect operations, we are working to better understand the risks and opportunities that a changing climate may bring, specifically what this will mean for animal health, the choices owners make for their animals and our business and supply chain.

This statement has been prepared to comply with the requirements of the Companies Act 2006 as amended by the Companies (Strategic Report) (Climate-related Financial Disclosure) Regulation 2022, and voluntarily includes climate-related financial disclosures consistent with the TCFD recommendations and recommended disclosures.

Governance – Board and Executive Committee Oversight

IVC Evidensia's Sustainability Strategy, known as the Positive Pawprint, is one of our key business initiatives and climate impact is one of the principal commitments within the Planet pillar of the strategy. An overview of the Positive Pawprint governance structure is provided below.

The Group Board has ultimate responsibility for ensuring that our sustainability strategy is implemented, and key sustainability and climate risks are effectively managed. Non-Executive Director, Chris Hadley has responsibility for sustainability and climate issues at Executive and Group Board level to ensure that environmental initiatives are implemented at Executive Committee level and across the IVC Evidensia Group.

Sustainability governance, performance against targets, and risk management are reviewed by the Board at least annually, including tracking progress on climate risk analysis and alignment with IVC Evidensia's science-based greenhouse gas targets.

Climate-related matters are considered as part of several key financial and strategic decision-making processes. As part of the Group's capital expenditure (Capex) investment strategy, there is a dedicated decarbonisation budget to support initiatives which cut greenhouse gas emissions and enable progress towards the Group's science-based greenhouse gas targets. In FY25, the Group Investment Committee approved investments in decarbonisation projects, including LED lighting, and heating controls, capnography equipment to support the adoption of low flow anaesthesia, and natural gas cremation oven burner modifications, all aimed at reducing the Group's overall greenhouse gas footprint.

In addition, for major investment decisions, including mergers, acquisitions and divestments, due diligence includes assessment of compliance with environmental laws, regulations, and standards. The Group continues to review ways to incorporate climate risk assessments as part of investment decisions and continues to consider use of internal carbon pricing.

The Group Investment Committee will continue to evaluate and approve investment proposals associated with the Group's decarbonisation strategy, working towards our FY30 targets to halve operational emissions.

Governance – Management's Role

The Group Board and Group Executive Committee delegate the management of sustainability strategy and climate related risks and opportunities to the Positive Pawprint Steering Committee. The Committee oversees the implementation of the Positive Pawprint Strategy (including climate related workstreams) and progress whilst also reviewing sustainability-related risks, developments, and opportunities on a quarterly basis. The Committee includes the Director of ESG and Sustainability, Regional Directors, Chief Medical Officer, Chief People Officer Country Level CEOs, HR Lead and Clinical Leads, Commercial and Finance teams. Climate-related risks are reviewed in-depth on an annual basis following updates to this Climate-related Financial Disclosure.

The Positive Pawprint Steering Committee is also supported by specialist workstreams which report progress, outcomes and opportunities to the Committee. These workstreams continue to facilitate the business in understanding and managing climate risk, implementation of its decarbonisation strategy and align this to the Group's commercial and clinical strategies. Workstreams include:

- Sustainability Initiatives in Crematoriums, with a focus on operational decarbonisation of this fossil fuelled process.
- Low Carbon Anaesthesia, looking at lower flow techniques, lower carbon gases and capture technology.
- Sustainable Procurement Engagement, working across procurement and with strategic suppliers to decarbonise our value chain.
- Farm Sustainability, with a focus on understanding the role of veterinarians in supporting farm clients adapting to a changing climate and changing requirements of food manufacturers and consumers.

Task Force on Climate-related Financial Disclosures (TCFD) Statement FY25

- One Health, with a focus on improving our understanding of the environmental impact of IVC Evidensia's clinical activities and the impact that a changing environment will have on disease patterns, welfare, drug availability and efficacy, thereby influencing our clinical approaches.

Each large market has a sustainability lead to ensure that sustainability risks and opportunities are embedded into their strategies and performance is monitored. We also have functional sustainability leads for specific areas of the business, including Procurement, Crematoriums and Finance.

We have a specialist Group Sustainability team, led by our Group Sustainability and ESG Director, and with specialist expertise on climate strategy. This team supports the regional teams in developing their own sustainability strategies, whilst also leading group-level projects across markets.



Risk Management

Climate-related risks are a principal risk to IVC Evidensia and have an ability to both directly and indirectly impact our business to varying degrees in the short (5 years – aligning with sustainability strategy planning), medium (15 years – aligning with broader strategic planning) and long (25 years – aligning with our 2050 net-zero target) term.

As part of the identification and assessment of climate-related risks and opportunities, we refer to market research and peer reviews, and consult multiple stakeholders across the business, including Clinical, HR, Property Procurement teams and Country Leads, resulting in a short list of risks and opportunities, which were analysed using two global warming scenarios. The six resulting risks and opportunities were presented to the Positive Pawprint Steering Committee in a brainstorming and action planning session.

The climate-related risks and opportunities are reviewed and assessed at least annually led by the Group Sustainability and ESG Director gathering stakeholder input as needed. A formal review is undertaken by the Positive Pawprint Steering Committee at least annually, to identify changes in the risk profile and report findings and recommendations to the Group Executive Committee and Group Board.

We have assessed both transitional and physical risks to IVC Evidensia. The physical risks from climate change include acute impacts, such as increased severity of extreme weather events such as floods and heatwaves, and chronic impacts, including changes in precipitation patterns and extreme variability in weather pattern and rising mean temperatures.

We have also assessed transitional risks across the business including policy, technology, market, and reputational risks. Some of these also represent opportunities for our Group. More detail can be found in the 'Climate-related Risks and Opportunities' section below.

The process to review and update climate-related risks and opportunities includes the consideration of a Group-wide horizon scanning document which is used to identify upcoming and existing legislation relevant for IVC Evidensia, and the Impacts, Risks and Opportunities identified in the double materiality assessment completed to prepare for CSRD disclosure.

Mitigation plans, included in table 3, are reviewed against our Positive Pawprint regional and country plans, ensuring that any additional actions identified throughout the year are included. Similarly, the annual risk and

opportunity review process includes reviewing mitigation plans, where relevant stakeholders are consulted for any additional actions identified by the Sustainability Team. Decisions on whether to mitigate, transfer, accept or control climate related risks are taken with reference to the Group's financial materiality thresholds. If signed off by the Positive Pawprint Steering Committee, any additional actions are added to regional and country plans, in collaboration with responsible teams and country leads.

The climate-related risk register is reported and reviewed under the Principal Risk 'Sustainability and Climate Change' as part of the Audit and Risk Committee reviews, where they are also compared to other business risks. Climate-related risks are managed using the same criteria for impact likelihood and materiality as other risks at IVC Evidensia and therefore we consider them to be integrated into our business risk processes. The management of the risk is monitored by the Audit and Risk Committee. Differences in risk assessment and management may occur due to the nature of the risk.

Further details about the Positive Pawprint Strategy, targets, progress and definitions can be found on the Sustainability page of our website.

Risk Assessment

Climate-related risks and opportunities are assessed by the Sustainability Team against the financial impact on the business and the likelihood of occurrence to provide an overall risk level between Low and High, across the short-, medium- and long-term for each climate scenario. The risks are then taken through an assessment of the potential revenue impact as detailed in Table 2.

Strategy

In FY24 we completed a Corporate Sustainability Reporting Disclosure (CSRD) aligned Double Materiality Assessment to develop a list of material ESG-related Impacts, Risks and Opportunities (IROs) through consultation with internal and external stakeholders, who identified climate change as one of the most important sustainability issues for IVC Evidensia. Further details on this assessment can be found in the 2025 Positive Pawprint Report.

Plans for transitioning to a low carbon economy

The majority of the Group's carbon emissions (70%) are the Scope 3 emissions associated with the products we use within our clinics, primarily pharmaceuticals and pet food, as well as medical consumables. Working in close partnership with our suppliers is therefore a core part of achieving our net-zero goal. We have a programme of regular engagement with our largest suppliers focused on tracking their progress to reduce their own emissions. During 2025, we introduced EcoVadis supplier assessments to support this supplier engagement. We have also set a contractual requirement for key suppliers to set GHG reduction targets aligned to IVC Evidensia's own targets.

The Group's Scope 1 & 2 emissions (accounting for 10% of our total GHG emissions) come from the energy we use to run our veterinary clinics, offices and crematoriums, our fleet, the anaesthetic gas used for surgical procedures in our veterinary clinics, and refrigerants.

Building emissions

Building emissions are associated with the heating and lighting of our clinics, hospitals, offices and crematoria. Procuring renewable electricity is a cornerstone of our strategy to minimise these emissions and, across the Group, 85% of the electricity we purchase is from renewable sources, working towards 100% by 2030. We are also working with our landlords to install solar panels and generate our own renewable energy.

We have made good progress to improve the energy efficiency of clinic lighting and heating systems. This involves installing smart meters to accurately track energy consumption, together with the installation of LED lighting and Building Management Systems, which can help us deliver significant savings; in a typical clinic around 40% for electricity and 20% for gas. LED lighting has been installed across our operations in the UK, Ireland, Germany, Netherlands and several provinces in Canada.

Crematoriums

Emissions from the Group's crematorium operations account for 31% of Scope 1 & 2 emissions, from the combustion of burning oil and natural gas in crematorium furnaces. A technical review of available lower carbon technology for the cremation of pets was finalised in FY25 by a specialist third party consultancy and results shared with our crematorium working group, including subject matter experts from our key markets. Recommendations included to, in the short term, focus on improving the efficiency of crematorium ovens by installing pilot flame

burners, which can reduce fuel usage by up to 18%, and improving operational efficiency of the crematorium process. In the medium term, switching from fuels such as kerosene and propane to natural gas and biofuel with lower associated carbon emissions by volume can reduce the carbon impact of existing crematorium ovens, together with a switch to lower carbon technologies such as electric ovens. Our crematorium working group is working on a plan to trial the recommendations, supported by capital investment from the Group. In FY25, capital investment has already been committed for the trial of pilot flame burners in France, and a more fuel-efficient mass cremator in the UK. During FY26, we hope to trial an electric oven in the Netherlands and aquamation in Germany. The results of these trials will be reviewed and used as the basis of a wider investment in decarbonisation across the Group's crematorium operations.

Anaesthetic gas

Emissions from anaesthetic procedures account for 17% of Scope 1 & 2 emissions. Adopting lower flow anaesthetic techniques gives us the opportunity to cut emissions, while also improving patient safety. In clinics adopting low flow anaesthesia, we expect a 25-40% reduction in carbon emissions from anaesthetic gas. During FY25, the Group invested in in-depth training to support this transition and allocated £500,000 in capital expenditure for improved monitoring equipment across UK clinics. Alongside this, we are trialling a new technology that aims to close the loop by capturing and recycling waste inhaled anaesthetic agent. The carbon capture equipment can capture up to 87% of anaesthetic gas, preventing it from being released into the atmosphere and therefore has the potential to support a material reduction in our emissions from anaesthesia. Further development is required to ensure the captured gas can be re-used in the future before we can account for it in our carbon footprint. During FY25, we extended the trial across our UK equine clinics and our UK referral hospitals and are evaluating options for further rollout.

In the medium term, we will continue to assess opportunities to transition to the use of anaesthetic agents with lower emissions, for example, from isoflurane to sevoflurane.

Fleet

The majority of travel is by our farm and equine vets, who can travel long distances to reach their patients and clients, and by our crematorium drivers, who again travel long distances to service their veterinary clients. In order to cut fuel emissions, we are undertaking a gradual transition of our fleet to vehicles with lower emissions, including hybrid and electric. Further analysis is required to determine the possible carbon reductions of replacing most of our fleet with electric vehicles.

Further information about our carbon reduction strategy is available in our 2025 Positive Pawprint Report. We do not currently plan to use carbon credits, however this is subject to review.

Scenario Analysis

We have used a scenario analysis and risk identification to provide us with a clearer understanding of the short, medium and long-term risks and opportunities for the business. To undertake this analysis, we used the Intergovernmental Panel on Climate Change (IPCC) Sixth Assessment Report (AR6) which states limiting warming to 1.5°C above pre-industrial levels is necessary to prevent the severe environmental consequences that are likely to occur in a 2°C warmer world and that catastrophic impacts would occur if temperatures rose by 4°C.

We have aligned our timeframes for this assessment with our Science Based Targets (SBT) approach, with the short-term aligning with our near-term SBT and long-term aligning with our proposed net-zero target. The modelled scenarios for climate risks and opportunities are displayed in Table 3, and in both scenarios, the Group is assumed to continue to grow.

Task Force on Climate-related Financial Disclosures (TCFD) Statement FY25

Table 1 Scenarios for the Identification of Future Climate Risks (not subject to audit)

SSP Pathway	RCP Pathway	2100 Warming	Description	Key Elements
SSP1 (Low challenges to mitigation and adaptation)	RCP 2.6	1.8°C	This scenario is aligned to the current commitments under the Paris Agreement. The world shifts towards a more sustainable path, emphasising more inclusive development, driven by an increasing commitment to achieving the United Nations Sustainable Development Goals. Implementation of carbon taxation system targeting carbon and a fully functional circular economy by 2100.	• Global Net-Zero reached in 2050 • Net negative emissions from 2050 onwards • Renewables account for more than half of the energy supply by 2050 • Few challenges to climate mitigation and adaptation
SSP2 (Medium challenges to mitigation and adaptation)	RCP 4.5	2.7°C	Intermediate GHG emissions scenario and has CO2e emissions remaining around current levels and peaking in 2040, with social, economic and technology not shifting substantially. Environmental systems continue to degrade but overall resource and energy intensity decline. Inequalities persist and there is continual reliance on fossil fuel.	• Emissions peak in 2040

Table 2 Financial Impact Summary

Potential Financial Impact				
Critical	High	Medium	Low	Very Low
>4% Annual EBITDA	2-4% Annual EBITDA	1-2% Annual EBITDA	0.5-1% Annual EBIDTA	<0.5% Annual EBIDTA

Climate Related Risks and Opportunities

Our Positive Pawprint Strategy is one of our key business initiatives and climate impact is one of the principal commitments within this.

We recognise that climate change is having a profound impact on global ecosystems, economies and populations and is an extremely important issue for IVC Evidensia, with the potential to impact our business in the short, medium, and long-term.

Task Force on Climate-related Financial Disclosures (TCFD) Statement FY25

Table 3 Modelled Scenarios for the Identification of Future Climate Risks and Opportunities

Area	Risk	Description	Warming	Short Term (Likelihood /Financial Impact)	Medium Term (Likelihood /Financial Impact)	Long Term (Likelihood /Financial Impact)	Mitigations	Financial Impact Assumptions
Transition Risks								
Policy and Legal	Increased pricing of GHG emissions	Emerging regulations around implementation of carbon pricing mechanisms and increasing the price and boundary of these mechanisms. IVC Evidensia will be increasingly exposed, particularly in the use of anaesthetic gas and fossil fuel to power crematoriums in our operations and potentially exposed to additional supply chain costs being passed on. Introduction of carbon pricing/tax mechanisms and/or cap and trade schemes in regions where our key suppliers operate might impact our suppliers' operating costs. This may, in turn, directly or indirectly increase the cost from our suppliers. Suppliers who do not have credible and robust GHG reduction strategies may face challenges continuing to operate, which may lead to disruptions to our supply chain.	1.8°C	H / Low	H / Very Low	H / Very Low	• IVC Evidensia have committed to reducing our Scope 1 and 2 emissions by 50%, Scope 3 emissions by 30% by 2030 (vs. a FY22 baseline) and achieve 100% renewable electricity by FY30. • We have implemented workstreams for emission hotspots such as anaesthetic gas, cremations and supply chain to facilitate decarbonisation activities across the Group.	Carbon pricing will rise in line with IEA projections for a 1.8°C warming scenario, and by half in a 2.7°C warming scenario.
			2.7°C	M / Very Low	M / Very Low	H / Very Low		
Technology	Transitioning to lower emissions technology	To reach IVC Evidensia's near-term Science Based Target (SBT) and Net Zero target, investment will be required to decarbonise capital assets, from buildings and crematorium ovens to anaesthetic machines. In addition, there will be associated costs for training personnel on carbon efficient processes and business model adaptation to modified processes. Efficiencies currently available will be sufficient for the short-term but to achieve net zero, technological advances are required in low carbon cremation, anaesthetic gas capture, electric vehicles, heating fuels, and recycling.	1.8°C	H	H	M	• Technological review of cremation technology available in the short, medium and long-term developing a decarbonisation road map and focussing on infrastructure closest to life expectancy. • Anaesthetic gas capture trials have continued to take place in FY25 in the UK, along with a roll out of low flow anaesthesia, reducing the need for anaesthetic gas. • Viability of electric vehicle usage is continuously assessed in each country and usage is increased where possible.	
			2.7°C	M	H	M		
Market	Changing customer behaviour	As consumer awareness and regulatory requirements for achieving decarbonisation grow there may be increased competition within the veterinary sector to offer lower carbon alternatives. Initially, we believe this may be seen in the petfood we place onto the market, both via our own brand and from other suppliers. Potentially this could be shown through an increased demand for meat alternatives within the pet food market. In addition, our reputation could be damaged if we do not (or are perceived not to) act responsibly with respect to the environmental and social impacts of deforestation through our supply chain and associated practices.	1.8°C	L / Medium	M / No impact	M / No impact	Supply chain engagement to continue with top pharmaceutical and nutrition providers. Engagement will expand from suppliers setting SBTs to include nature-related impacts (water, land use change, etc). Own Brand Sustainability Principles focussing on packaging, manufacturing environmental impact, animal welfare, aquaculture and wild fisheries to facilitate implementing the voice of the consumer. Continue to work with key suppliers to review opportunities to carbon footprint our existing Own Brand Nutrition Products and identify opportunities to reduce the carbon footprints including the development of options for communicating lower carbon products. Develop alternative protein-based strategy to meet evolving consumer expectations.	The business continues to grow around the current rate. Customers will continue to purchase pet food from suppliers with science-based carbon targets.
			2.7°C	L / Low	M / No impact	H / No impact		

Task Force on Climate-related Financial Disclosures (TCFD) Statement FY25

Area	Risk	Description	Warming	Short Term (Likelihood /Financial Impact)	Medium Term (Likelihood /Financial Impact)	Long Term (Likelihood /Financial Impact)	Mitigations	Financial Impact Assumptions
Physical Risks								
Acute	Increased severity of extreme weather events such as draughts, floods, heatwaves and coldwaves	Extreme weather events from flooding through to heatwaves have an ability to impact upon the >2,400 locations IVC Evidensia operate from. In some instances, weather events may hinder personnel from attending work, leave customers unable to reach our locations or make it difficult for our teams to reach patients due to flooding. Heatwaves also have a potential to impact upon operating theatres, onsite animal housing and those locations where we store pharmaceutical and nutraceutical products which are generally required to be stored below 25°C, a temperature which may commonly be exceeded in the future heatwaves and require the installation and operation of additional air conditioning units across our sites. Further analysis is required to understand IVC Evidensia's exposure to supply chain distribution and locations to extreme weather.	1.8°C	L	M	M	• Installation of energy efficiency measures across the real estate to reduce electricity consumption but ensure temperatures remain suitable for pharmaceutical storage, animal and human welfare. • Determine sites at risk of extreme weather events and reduced water supply.	
			2.7°C	M	H	H		
Chronic	Longer term shift in climatic patterns	Long-term shifts in climate patterns may result in the physical damage of IVC Evidensia properties, impact business continuity or lead to financial investment in preventative measures. This includes the potential for sea level change and/or flood zone implications on operations. In addition, key suppliers in areas such as pharmaceutical, nutraceutical and nutrition are dependent upon stable weather conditions and water supply to ensure production. The potential expansion of water scarcity, drought and quality water have potential to impact upon our supply chain, especially in a higher emissions scenario.	1.8°C	-	L	L	• Started implementing enhanced supplier due diligence approach in FY25 to facilitate ESG supply chain risk and compliance. • Determine sites at risk of changes in climate patterns and reduced water supply.	
			2.7°C	-	L	M		
Transition Opportunities								
Market	Increased revenue / consultations from: • shift in the volume of infectious diseases • increased distribution of tick and fleas • extreme weather impacts on animals	Climate has influenced, and will continue to influence, the occurrence and severity of infectious diseases in the natural and agricultural systems. This is likely to include an increase in vector-borne diseases, waterborne, windborne, and enteric infections. The distribution of ticks and fleas across Europe and Canada has the potential to increase, both in spatial distribution and duration, due to more temperate climates in areas like the Nordics and North America. Both above trends are likely to lead to increasing demand for veterinary advice. Extreme weather will likely see an increase in consultations directly from incidents such as burned paws, dehydration and heat stress (particularly in brachycephalic dogs).	1.8°C	L	L	M	• Additional services being offered including routine faecal testing by farm vets to support tailored prescription of parasite treatment • Awareness campaigns and testing being offered to clients in key markets including Canada and the Netherlands • Ongoing communication of Pet Health Plans which offer pet owners tailored parasite treatment appropriate to the local level of risk	.
			2.7°C	L	M	M		

Note: H: High, M: Medium, L: Low

Task Force on Climate-related Financial Disclosures (TCFD) Statement FY25

Further analysis is required to quantity our Technology Transition Risk, Acute and Chronic Physical Risks, and our Transition Opportunity from Shifting Disease Patterns. Based on our analysis to date, the business is sufficiently resilient to the impacts of climate change under both climate scenarios considered with the identified risk mitigation measures being implemented.

Metrics and Targets

Our targets to reduce absolute Scope 1 and 2 by 50% and Scope 3 by 30% (from a 2022 base year) by 2030, and to become net zero across scope 1, 2 and 3 by 2050 against our FY22 baseline have been validated by the Science Based targets initiative. We also have a target specifically focused on the sourcing of renewable electricity, we achieved 85% renewable electricity in FY25, this will rise to 100% by FY30.

By reducing our emissions, we are both doing our part to reduce GHG emissions to the atmosphere but we are also mitigating the potential impact of policy or regulatory frameworks that could put a price on our emissions. We manage our climate-related risks and opportunities as part of the SBTi targets and don't yet set risk- and opportunity-specific metrics and targets. This approach may be updated as we continue assessing the financial materiality and likelihood of the risks and opportunity against other principal risks.

We commenced recording our GHG emissions in FY22 and our business has been rapidly growing since this time. In FY25, we recalculated our baseline emissions to account for acquisitions and divestment since our baseline year, and implemented a new carbon accounting tool to improve the robustness and auditability of our reporting.

The majority of our GHG footprint sits within Scope 3 and especially within the pharmaceutical and nutrition supply chain. During FY25, our Supply Chain Engagement Programme continued to work with our pharmaceutical suppliers and started including our nutrition suppliers, focusing on their commitments to decarbonise via the Science Based Targets initiative (SBTi), determining when supplier specific emissions data (and hotspot reductions) will be available and establishing opportunities for joint sustainability workstreams.

We are also aware that the potential chronic physical risks associated with suppliers who have a larger nature related footprint (i.e. freshwater, land, oceans, waste, etc) for example in nutrition manufacturing and will continue working with our nutrition suppliers to address risks in these areas. We are continuing to review nature-based impacts associated with our supply chain, and this will become more of a focus during the year ahead.

IVC Evidensia does not currently use internal carbon pricing, however this continues to be reviewed as our climate strategy develops. The achievement of our carbon targets is not currently incorporated into remuneration policies, but this is an area which also remains under regular review.

Operational Emissions (Scope 1 and 2)

Overall, we have delivered a 20% reduction against our FY22 Scope 1 and 2 emissions, this has predominately been delivered through renewable energy procurement s. In addition, we are seeing a 17% reduction in onsite combustion for crematorium fuels from energy efficiency activities across the Group, reduced emissions (-13%) from anaesthetic gas, and reductions in our fleet emissions (-11%). Emissions associated with heating and hot water have increased 28% since FY22 and will be a focus as part of our carbon reduction plans.

We have considered the cross-industry metrics of the TCFD implementation guidance and do not currently consider them to be relevant.

Value Chain (Scope 3)

As we continue to grow and acquire businesses, we are seeing an increase in overall procurement costs. This is directly illustrated through our current spend-based accounting approach to Scope 3. Since FY22 we have seen a 10% increase in Scope 3 emissions. In addition, we will continue

improving our calculation accuracy in FY26 with a revised carbon tool allowing supplier specific emission factors.

We will continue our supplier engagement programs with our pharmaceutical, nutritional and white label suppliers.

We are at the start of our emissions reduction journey and our progress with delivering emissions reductions. Our full GHG inventory is provided in Table 4.

Table 4 GHG Inventory

Scope	Emissions (tCO_2e)			
	FY22*	FY23*	FY24*	FY25**
Scope 1	48,087	46,465	43,516	44,848
Scope 2 (Market Based)	15,001	9,619	14,586	5,503
Scope 3	429,317	436,469	448,461	470,503
TOTAL	492,405	492,552	506,564	520,854

Note: * FY22, FY23 and FY24 have been restated following updated calculation methodologies and the collection of additional data streams across all scopes. In addition, we have updated FY22 data to account for acquisitions, and all years to account for divestments since FY22.

** In FY25, we have used the latest 2025 CEDA emission factors for our spend-based emissions.

The following scope 3 categories have been determined to be material to our business and are therefore included in our greenhouse gas inventory:

- Category 1: Purchased Goods and Services
- Category 2: Capital Goods
- Category 3: Fuel- and Energy-related activities
- Category 4: Upstream Transportation and Distribution
- Category 5: Waste generated in Operations
- Category 6: Business Travel
- Category 7: Employee Commuting
- Category 12: End of Life

Category 9: Downstream Transportation and Distribution is currently being assessed for inclusion in our future footprints.

We use the World Business Council for Sustainable Development (WBCSD) Greenhouse Gas (GHG) Protocol Corporate Standard to guide our reporting of Carbon Dioxide equivalent (CO2e) emissions. In addition, we utilise supporting standards including:

- GHG Protocol Scope 2 Guidance, 2015
- GHG Protocol Corporate Value Chain (Scope 3) Standard, 2011

We report where we have Operational Control and report our emissions in CO2e emitted across our financial year (1 October to 30 September).